UCN2 and myopathy: Because anti-SRP myopathy and anti-HMGCR myopathy are caused by MSAs, new biotherapies targeting B lymphocytes, such as rituximab (9, 10), ofatumumab (12), and belimumab (13), have been used to treat refractory IMNM, with positive responses in some patients.